Valneva (NASDAQ:VALN - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.54) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.32), Zacks reports. The business had revenue of $56.48 million for the quarter, compared to the consensus estimate of $55.64 million. Valneva had a negative net margin of 4.35% and a negative return on equity of 3.93%.
Valneva Trading Up 3.6 %
VALN stock traded up $0.26 during midday trading on Monday, hitting $7.43. The company had a trading volume of 28,389 shares, compared to its average volume of 26,063. The stock has a market cap of $603.77 million, a price-to-earnings ratio of -57.15 and a beta of 1.93. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70. The stock's 50 day moving average price is $6.40 and its 200 day moving average price is $5.59.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on the stock. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Valneva in a research note on Friday. Guggenheim cut their price target on shares of Valneva from $17.00 to $15.00 and set a "buy" rating for the company in a research report on Monday.
Check Out Our Latest Analysis on Valneva
Valneva Company Profile
(
Get Free Report)
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.
Featured Articles
Before you consider Valneva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Valneva wasn't on the list.
While Valneva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
